Affimed to Present at Upcoming Investor Conferences
September 02 2020 - 6:30AM
Heidelberg, Germany, September 2, 2020 –
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer, today announced that the company’s management will
participate in the following investor conferences during the month
of September 2020:
2020 Wells Fargo Virtual Healthcare Conference
(September 9-10, 2020) Date: Wednesday, September 9, 2020
Presentation Time: Fireside chat with Dr. Jim Birchenough at 8:00
a.m. Eastern Time Citi’s 15th Annual BioPharma Virtual
Conference (September 8-11, 2020) Date: Wednesday,
September 10, 2020 Affimed will host meetings with investors at the
conference
Cantor Fitzgerald Virtual Global Healthcare Conference
2020 (September 15-17, 2020)Date: Thursday, September 17,
2020 Presentation Time: 12:40 p.m. Eastern Time Oppenheimer
Fall Healthcare Life Sciences and Med Tech Summit (September 21-23,
2020) Date: Monday, September 21, 2020 Presentation Time:
3:20 p.m. Eastern Time Location: Virtual
Webcasts of each presentation may be accessed on Affimed’s
website at https://www.affimed.com/investors/webcasts_cp/. For more
information on the conferences or to schedule a one-on-one meeting
with Affimed management, please contact your conference
representative or Alex Fudukidis via email at
a.fudukidis@affimed.com or phone at (917) 436-8102.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer. Affimed’s fit-for-purpose ROCK® platform allows
innate cell engagers to be designed for specific patient
populations. The company is developing single and combination
therapies to treat hematologic and solid tumors. The company is
currently enrolling patients into a registration-directed study of
AFM13 for CD30-positive relapsed/refractory peripheral T cell
lymphoma and into a Phase 1/2a dose escalation/expansion study of
AFM24 for the treatment of advanced EGFR-expressing solid tumors.
For more information, please visit www.affimed.com.
Investor & Media Contact:
Alex Fudukidis Head of Investor Relations E-Mail:
a.fudukidis@affimed.com Tel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024